Statistical Table 13: Prevalence of HIV infection (%) among injecting drug users under age 25, in the EU (sample sizes between brackets)

Transcription

1 Statistical Table 3: Prevalence of HIV infection (%) among injecting drug users under, in the EU (sample sizes between brackets) HIV IDUs under Belgium, French Community / 5.0 (9) 5. (98) 3.4 (87). (92) (7) 2.5 (40) (4) (7) SR self-reported test results; > 50% missing data. Belgium, French Community - Charleroi (04) General practitioners; 0 Belgium, Flemish Community (67) (4) (72).5 (66) 2.4 (42) 2 Belgium, Flemish Community (24).5 (478) low-threshold services and hospitals; > 50% missing data. 3 Belgium, Flemish Community - Antwerp (6) low threshold services; 8

2 Denmark, Funen / (n.a.) prison; screening serum.

3 Greece, National / (54) self-reported test results. Greece, National (5) 2

4 Spain, National excl. communities of Madrid and La Rioja / 20.3 (2025) 7.9 (862) 6.2 (33) 6.3 (40) 6.8 (827) 4.7 (667), 2

5 France, National / 6.3 (08) 2.5 (770) SR self-reported test results. France, National 7.6 (58) SR Needle exchanges; selfreported test results. 3 France, Bordeaux Cayenne Dijon Fort-de France Lille Lyon Marseille Paris Renne La Reunion Toulouse 3. (65) SR Needle exchanges, low threshold services; selfreported test results. 4

6 Ireland, Dublin / 0.2 (438) Drug treatment centre Trinity Court, first attendees ; screening serum; ever- IDUs.

7 Italy, Sardegna Sicilia Calabria Campania Lazio Marche Toscana Emilia Romagna Liguria Friuli Piemonte Puglia / 2.0 (83) sample study in 2 regions; data are for ; screening serum. 3

8 Netherlands, Rotterdam / 7.4 (23) (2) Drug treatment centers, methadone post and street; screening saliva. 5, 0 Netherlands, Zuid-Limburg region; Heerlen and Maastricht 8.6 (35) Netherlands, Utrecht (25) (0) needle exchanges, low threshold services, methadone post, street prostitution project, street and via other IDUs; (994/96 saliva, 999 serum). low threshold services and methadone post; screening saliva. 6, 7 Netherlands, Arnhem (9) Methadone care, low threshold services, street and street prostitution; screening saliva. 3

9 Austria, National / (56) 5.8 (87) 2.7 (75) (66) 4.4 (69) 2.0 (50) 2.4 (4) 2.6 (39).9 (53) 4.9 (4) Overdose deaths; Austria, Vorarlberg (9) (8) (0) (7) () (3) (2) Inpatient drug treatment, screening serum. 2

10 Portugal, Lisbon-Xabregas /. (27) 5.6 (8) 8.3 (2) Portugal, Porto 56.7 (30) 3 Portugal, Coimbra 6.9 (43) 7.4 (27) public health laboratory, pregnant IDUs; 2 Portugal, Santarém 36 (4) 7

11 Finland, Helsinki / (2) 3.4 (46) (285) Needle exchanges; Finland, Tampere (282) (233) Needle exchanges;, 8 Finland, Vantaa (2) (76) Needle exchanges; Finland Vantaa (39) Needle exchange, screening saliva, 8

12 UK, England and Wales / (968) 0. (927) (908) 0.2 (646) (87) (647) 0. (835) 0. (938) (85) (625) needle exchanges, low threshold services, primary care and outreach; screening saliva. UK, England and Wales exd. London 0.3 (9) 0. (840) 0.2 (829) 0.2 (576) (72) (595) 0. (784) (843) (754) (570) needle exchanges, low threshold services, primary care and outreach; screening saliva. UK, England and Wales excl. London (205) Community surveys; current IDUs, screening saliva. 2, 3 UK, London.8 (57) (87) 2.5 (79) (70) (05) (52) (5). (95) (6).8 (55) needle exchanges, low threshold services, primary care and outreach; screening saliva. UK, London (22) Community surveys, prisons, current IDUs, screening saliva. 2, 3 UK, London (37) Community survey, female current IDUs; screening saliva. 7

13 UK, Scotland / (476) 0.3 (853) (74) 0.3 (674) Named HIV tests; 5 Notes:. Sample size is the number of positive plus negative tests (total valid tests). Prevalence is number positive divided by total valid tests, excluding missing values. Prevalence from sample size under 50 is not reliable. 2. Self-reported test results are less reliable than biological test results. Prevalence is number reporting a positive test result divided by the number reporting a positive or negative result. 3. Having health problems is one selection criterion for admission to drug treatment in some countries or cities (Greece, Portugal, Rome), due to long waiting lists or special programmes for infected IDUs, this may result in upward bias of prevalence. Prevalence from treatment data should therefore be interpreted in combination with non-treatment data. 4. Data sources with no information on injecting status were excluded as far as possible, as such prevalence can severely underestimate prevalence among injectors in the same source. Some such sources were however included if samples were large or they provided trends over time, in which case it is indicated that injecting status is unknown and prevalence among injectors may be underestimated. * See Box 6 OL: Data sources prevalence ( for details of sources. =diagnostic testing; =specific prevalence study; SR=prevalence study based on self-reported test results